CAMP4 Therapeutics Corp. (CAMP), a clinical-stage biopharmaceutical company, Thursday, provided an update on its lead investigational asset CMP-CPS-001.
CMP-CPS-001 is an antisense oligonucleotide therapeutic candidate for treating Urea Cycle Disorders (UCD), a rare genetic metabolic disorder that prevents the body from safely removing ammonia.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com